Replies to post #223871 on Biotech Values

[DewDiligence]

(RVNC)—My $24B estimated value of AGN’s Botox franchise from 2017 (#msg-127654469) was clearly too low, as asserted in #msg-147281766 (from Mar 2019).

https://twitter.com/DewDiligence/status/1143522097546825728